dow up 280 julia boorstin is here and phil lebeau from dallas, following tesla and ford earnings meg terrell carl, twitter shares are soaring 17% on top and bottom line, despite user growth falling short of expectations. the earnings of 21 cents a share are 7 cents better than wall street projections revenue of $758 million for advertising. looking at monthly active users, numbers fell more than expected, declining more than 9 million in the course of the quarter to 326 million. 4 million short of expectations. the company expects another mid single digits million decline in the fourth quarter, daily active users grew 9%. jack dorsey says both daily and monthly user numbers were impacted, but the company's focus on cleaning up spam and fake accounts, saying improving the health of the platform is their top priority, saying it is key for the long term growth of twitter. guys, back over to you. >> julia, thank you. let's get to phil lebeau, he is looking at tesla and ford earnings phil, both those stocks moving higher >> they're moving higher start with tesla you knew tesla would report higher

but as our meg terrell found, there are new advances that could be a game changer. it's this week's "cover story." >> reporter: for 13-year-old will brody a bite of the wrong food could be fatal. >> my peanut allergy is the one that i have. it's anaphylactic which means i could die or i take my epipen and go to the hospital. >> reporter: will has dangerous allergies. according to the cdc, the prevalence of food allergy, the most common cause of anaphylaxis rose 70% from 1997 to 2016 in kids younger than 18 allergic reactions are causing more hospital visits too an increase of more than four fold in a decade peanuts are the worst culprit. >> peanut allergies affects approximately 1 1/2 to 4.5% of children. >> reporter: two new treatments may reach the market as soon as next year. from biotech communities both introduced small amounts of peanut protein to patients over time with the goal of building up tolerance. will brody is in a clinical trial. >> at first we almost didn't do it because it was eating the thing i was avoiding at all costs. >> reporter: every day he

joining us, meg terrell. >> there was a cancer research conference this weekend, investors are lookingext friday, a big update on alzheimer's. for clinical trials. biogen will present further evidence on their drug both company stocks sank as there was confusion over the data investors looking for more clarity friday whether they get it, could cause stock swings either direction. early next week, watch alkermes and sage therapeutics. documents come out a few days before, tuesday, watch alkermes, and wednesday watch sage whose drug would be the first approved specifically for postpartum depression meetings and votes are thursday and friday >>> no shortage of bio and pharma stocks to watch out of the conference in europe and other updates. bristol meyers is down after the fda extended review. smaller companies are down on data from the conference betting on biotech can be like buying a lottery ticket, there's major down side risk as well guys, back to you. >> i'm looking at moves in biotech stocks we just had a debate about shift from growth to value looking at the biotech names, how sho

meg terrel has the story >> hey, joe. sector has significantly underperformed it may be the rising rates or fear of rising rates. many bio-tech investors say because of the it, the higher interest rates could mean smaller performance. according to the bio-tech, the ibb influence said by large caps and the x large companies. despite the fear of higher interest rates, mapping 20 years of bio-tech performance with the ten-year yield, they actually found when rates rise, bio-tech stocks generally do as well. what they say is more interesting is the investor's appetite for risk which may play a bigger role in the environment that we're seeing, guys. and saying they feel paralyzed looking at the market. they just don't know it could be a really great day they just don't know what's going to happen. >> which plays into the whole idea for the market's tolerance for risk >> yes >> so watch the vix. >> big night last night. the whole pharma category. >> what? >> yes >> i missed it >> did you get all of them >> in the question, it h